ABBV - AbbVie Inc.
Close
180.07
-12.800 -7.108%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$192.87
-12.80
-6.64%
Fundamental analysis
54%
Profitability
50%
Dept financing
50%
Liquidity
12%
Performance
71%
Performance
5 Days
2.52%
1 Month
1.66%
3 Months
-5.89%
6 Months
5.42%
1 Year
16.17%
2 Year
10.44%
Key data
Stock price
$180.07
DAY RANGE
$178.43 - $192.87
52 WEEK RANGE
$155.21 - $207.32
52 WEEK CHANGE
$16.22
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news